Home

Steven L. Hoerter

CIK 1533451 · President and CEO · last filed 2026-08-04

Steven L. Hoerter is a President and CEO who has filed 74 SEC Form 4 insider transactions across 8 companies since 2012. The most recent filing, for MBX, was dated Aug 4, 2026. Across all open-market trades the lifetime net is −$9.2M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $6.4M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$6.44M

Companies

8

Total Filings

74

Lifetime Open-Market Net

-$9.16M

Filer Profile

Reported Address
C/O DECIPHERA PHARMACEUTICALS, INC.
200 SMITH STREET
WALTHAM, MA 02451
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
MBX President and CEO 102,938 $59.02 $6.08M $265.0K 10 2026-08-04
CCCC Director — $3.51 — $0 3 2026-06-26
ORIC Director — $12.04 — $0 6 2026-01-06
Deciphera Pharmaceuticals, Inc. (DCPH) Delisted President and CEO 72,763 $25.59 $1.86M -$1.33M 21 2024-06-11
CONSTELLATION PHARMACEUTICALS INC (CNST) Delisted Director — $33.99 — $0 4 2021-06-04
AGIO Chief Commercial Officer 10,941 $33.60 $367.6K -$3.75M 16 2019-03-05
Ignyta, Inc. (RXDX) Delisted Director — $199.92 — $0 2 2017-06-19
Clovis Oncology, Inc. (CLVS) Delisted See Remarks 0 $0.08 $0 -$4.34M 9 2015-03-09

Recent Filings

74 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-08-04 MBX Grant (A) +71,000 $0 EDGAR
2026-06-26 CCCC Grant (A) — $0 EDGAR
2026-06-05 MBX Grant (A) — $0 EDGAR
2026-05-04 MBX Grant (A) +11,938 $0 EDGAR
2026-04-22 MBX Grant (A) — $0 EDGAR
2026-04-22 MBX Grant (A) — $0 EDGAR
2026-01-06 ORIC Grant (A) — $0 EDGAR
2025-11-25 MBX Grant (A) — $0 EDGAR
2025-11-07 MBX Grant (A) — $0 EDGAR
2025-10-20 MBX Buy (P) +20,000 $265.0K EDGAR
Showing 1–10 of 74
Page 1 of 8
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.